Product
Ozurdex (dexamethasone intravitreal implant) 0.7 mg
Approval Date
June 18, 2009
Release Date
Third Quarter 2009
Company
Allergan, Inc.
Class
Corticosteroid
Indication
For the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
Active Ingredient
Dexamethasone
Agency Roster
PacificCommunications
Also in the Pipeline (courtesy of Adis R&D Insight)
Drug: AMD Fab
Manufacturer: Genentech/ Novartis Ophthalmics
Indication: Age-related macular degeneration
Active ingredient: Ranibizumab
Phase: Launched
Source: Wolters Kluwer Health
Pharmacology
Detailed clinical information withheld for review by MPR’s clinical advisory board and will be added as soon as it becomes available.
Clinical Trials
Detailed clinical information withheld for review by MPR’s clinical advisory board and will be added as soon as it becomes available.
Adverse Reactions
Detailed clinical information withheld for review by MPR’s clinical advisory board and will be added as soon as it becomes available.
Adults
Detailed clinical information withheld for review by MPR’s clinical advisory board and will be added as soon as it becomes available.
Children
Detailed clinical information withheld for review by MPR’s clinical advisory board and will be added as soon as it becomes available.
Contraindications
Detailed clinical information withheld for review by MPR’s clinical advisory board and will be added as soon as it becomes available.
Precautions
Detailed clinical information withheld for review by MPR’s clinical advisory board and will be added as soon as it becomes available.
Interactions
Detailed clinical information withheld for review by MPR’s clinical advisory board and will be added as soon as it becomes available.
